Company Information

Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer. By combining multiple powerful platforms, Agenus has established a highly integrated approach for the discovery, development and manufacture of monoclonal antibodies that modulate targets of interest. In addition, the Company’s cancer vaccine program includes three proprietary platforms focused on individualized and off-the-shelf vaccines uniquely designed for each patient. Agenus’ broad portfolio of novel checkpoint and other immuno-modulatory monoclonal antibodies, vaccines and adjuvants, work in combination to provide the opportunity to create best-in-class therapeutic regimens. The Company has formed collaborations with Merck and Incyte to discover and develop multiple checkpoint antibodies.


Stock Chart
Events and Presentations
Thursday, August 3, 2017
11:00am - 12:00pm EDT
Wednesday, June 28, 2017
5:00pm - 6:00pm EDT
Tuesday, June 6, 2017
10:30am - 10:55am EDT

Agenus will present at the Jefferies 2017 Global Healthcare Conference on Tuesday, June 6th at 10:30 a.m. EST in New York City, USA.